Vaccination News Home Page

http://news.bmn.com/news/story?day=021023&story=2

 
Research
Tools
Reviews Journal
Collection
News &
Comment
Books &
Labware
Science
Jobs
Web
Links
news.bmn.com Latest
Updates
Today's
News
Magazine Conference
Reporter
Commentary Journal
Scan
Special
Report
My E-mail
Alerts
Section
Search
  My BMN My BMN Exit Exit  
  Send Feedback to BMN Feedback Help System Help  


 

Today's News
 Front Page
 News Archive
 Send us News Tips


 

Quick Site Search

 

Advanced site search


 

 


 

- 23 October 2002
Today's News Stories
News Archive
     
Flawed studies fail to nail polio vaccine

22 October 2002 10:28 EST

by Apoorva Mandavilli

SV40
[caption and credit]

There is "strong" evidence that the simian virus SV40 can cause human cancers, an Institute of Medicine (IOM) panel reported today. But despite the biological evidence, epidemiological studies to date are "inadequate" to conclude that contaminated polio vaccines are the source of the virus, the panel said.

Between 1955 and 1963, as many as 30 million children and adults received inactivated polio vaccine tainted with SV40, previously identified as a harmless pathogen in the rhesus macaque. Researchers discovered the contamination in 1960 and, by 1963, cleared the virus-ridden vaccines.

In the past few years, however, an increasing number of reports have suggested that SV40 is to blame for higher rates of mesothelioma, ependymomas, bone cancers and non-Hodgkin's lymphoma. In laboratory studies, researchers have shown that the virus can produce those tumors in rodents, nonhuman primates, and cultured human cells.

While some researchers have reported that the virus is detectable in tumors, others have published directly contradictory data, maintaining that the virus is either not present in the tumors or, if present, does not cause tumors.

After reviewing scores of such opposing studies, the IOM panel conclude that there is sufficient evidence to suggest that SV40 is a human pathogen and a strong transforming agent.

The conclusion exactly echoes an independent report from a meeting held last year to discuss the controversial issue, notes Michele Carbone, associate professor of pathology at Loyola University in Chicago.

"Both [reports] concluded that in fact SV40 is not only present in human tumors but that there's reason to believe that SV40 causes cancer," he told BioMedNet News. Carbone is author of several reports linking SV40 to human cancers, particularly human mesotheliomas.

Panel members are careful to point out that the presence of the virus in tumors does not by itself demonstrate a causal link. Tumors often contain viruses that are unrelated to their origin, notes Marie McCormick, professor and chair of maternal and child health at the Harvard School of Public Health, and chair of the IOM panel.

Most of the epidemiological studies on SV40 have also shown no association between contaminated vaccines and tumors, McCormick adds. But because the studies were flawed, and relied on inconsistent methods, panel members were "quite unwilling to come down on the side of no-evidence," she said.

Instead, the panelists conclude that the evidence is "inadequate to accept or reject" that virus-contaminated vaccines are to blame for certain cancers. Before embarking on further epidemiological studies, they recommend that researchers develop more sensitive and reliable tests for SV40.

Although polio vaccines have been free of the virus since 1963, says McCormick, developing such tests is critical. The virus has been detected in people too young to have received contaminated polio vaccine, suggesting that they have been exposed to the virus through other means, including person-to-person transmission from a vaccinated individual.

"Can [SV40] be transmitted from humans to humans? That, I think, is the big question and not answered at all," said McCormick. The viral epidemiology group at the US National Cancer Institute is now studying how the virus is transmitted, she adds.

Whatever the origin of the virus, Carbone says he is more interested in studying how the virus causes cancer.

Carbone and others have previously shown that the viral protein Tag binds and inactivates the tumor-suppressor proteins p53 and Rb. But inhibition of p53 and Rb is not enough to cause tumors, Carbone says.

In an article in press in Oncogene, Carbone reports that SV40 induces Notch1, a key regulator of development. Pharmacological inhibitors of Notch1 inhibit tumor growth in sv40-positive human mesothelioma cell lines, the researchers found. "We hope this can be a useful target in the clinic," Carbone said. "Notch1 may be the missing link to understanding how [SV40] causes cancer."

Picture caption and credit:
Transmission electron micrograph of polyomavirus SV40, CDC/Dr. Erskine Palmer.


 
 
Send us your comments for publication.
 
 
Sign up for BioMedNet News weekly email alerts.


 

 





 

See also:
SV40, polio vaccine, and cancer: Now beyond coincidence?
Apoorva Mandavilli
BioMedNet News & Comment, 9 April 2002

Association of SV40 with human tumors
Klein G, Powers A, Croce C
Oncogene, 2002 Feb 21:1141-9

Simian virus 40 and human tumors: It is time to study mechanisms
Carbone M
J Cell Biochem, 1999 Dec 76:189-93

A multicenter evaluation of assays for detection of SV40 DNA and results ...
Strickler HD
Cancer Epidemiol Biomarkers Prev, 2001 May 10:523-32

Simian virus 40: The link with human malignant mesothelioma is well established
Carbone M, Rizzo P, Pass H
Anticancer Res, 2000 Mar-Apr 20:875-7
 




 
Today's News Stories
News Archive


BioMedNet
Home
News &
Comment
My BMN
 
Help System
 
Send Feedback to BMN
 
Information for Advertisers © Elsevier Science Limited 2002

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.